J&J/Oxford AZ vaccine reactions and relationship to heparin

After the J&J vaccine pause, reports seemed to indicate that the clotting reaction some people had is related to a rare reaction that can occur with some people when given heparin. I don't know, but I am assuming the Oxford vaccine's reactions are due to a similar issue.

What I'm wondering is, how strong is the correlation or relationship? Does any data indicate that people who cannot be given heparin should also not be administered these vaccines, or is the relationship too tenuous/not enough data?

Posted May 21, 2021, 9:22 AM UTC

92
amothep8282PhD, AEMT•

See this case report for a good overview.

Essentially, previous exposure in life to an adenovirus generates antibodies that can cross react with platelet factor 4 (PF-4), which is the same target of antibodies generated in heparin induced thrombocytopenia (HIT).

There is no consensus recommendation for patients who have manifested HIT in receiving an andenovirus vaccine, however, I would have great pause in doing so because we have no idea if PF-4 antibodies already existing in HIT patients will cross-target the adenovirus for destruction, and thus abrogate vaccine efficacy.

In the case report above, "The generation of procoagulant platelets was PF-4 and heparin dependent." This suggests there is some common mechanism between HIT and VITT, so at this point, caution would be warranted in known patients who have experienced HIT, but again, no society or body that I know of has made a definitive statement or recommendation.

7
jackruby83PharmD, BCPS, Transplant•

From CDC recs:

People with a history of thrombosis or risk factors for thrombosis

Although the etiology of TTS associated with the Janssen COVID-19 vaccine is unclear, it appears to be similar to another rare immune-mediated syndrome, heparin-induced thrombocytopenia (HIT). Until more information becomes available, experts advise that persons with a history of an episode of an immune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as HIT, should be offered another FDA-authorized COVID-19 vaccine (i.e., mRNA vaccine) if it has been ≤90 days since their illness resolved. After 90 days, patients may be vaccinated with any FDA-authorized COVID-19 vaccine

2